Cognitive disorders

KeifeRx Receives FDA Acceptance of Investigational New Drug for Phase 3 Study of Nilotinib BE in Early Alzheimer's Disease

Retrieved on: 
Friday, July 30, 2021
Psychiatry, Cognitive disorders, Branches of biology, Learning disabilities, Psychiatric diagnosis, Neuroscience, Dementia, Orphan drugs, Nilotinib, Alzheimer's disease

The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.

Key Points: 
  • The safety and efficacy of a Nilotinib BE will be investigated in individuals with dementia due to Alzheimer's disease with abnormal levels of brain amyloid and supporting clinical diagnosis of early Alzheimer's disease.
  • "Our Phase 3 study provides us the opportunity to gain valuable insights about the potential effectiveness of Nilotinib BE in treating early Alzheimer's."
  • KeifeRx will launch a national, multicenter, placebo-controlled, double-blind study of Nilotinib BE in early Alzheimer's disease.
  • The primary objectives of the study are to investigate the safety and efficacy of Nilotinib BE on the progression of dementia in early Alzheimer's disease.

Highlights From The Alzheimer's Association International Conference 2021

Retrieved on: 
Thursday, July 29, 2021
Psychiatry, Cognitive disorders, Psychiatric diagnosis, Branches of biology, Learning disabilities, Neuroscience, Dementia, Alzheimer's Association, AAIC, Alzheimer's disease

DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.
  • Other new data reported at AAIC 2021 included:
    Improving air quality may reduce dementia risk.
  • "As the leading voluntary health organization in Alzheimer's research, care and support, the Alzheimer's Association believes we're living in a new era of advancement.
  • The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

Highlights From The Alzheimer's Association International Conference 2021

Retrieved on: 
Thursday, July 29, 2021
Psychiatry, Cognitive disorders, Psychiatric diagnosis, Branches of biology, Learning disabilities, Neuroscience, Alzheimer's Association, Dementia, Aging-associated diseases, AAIC, Alzheimer's disease

DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • DENVER, July 29, 2021 /PRNewswire/ -- Research presented at the Alzheimer's Association International Conference (AAIC) 2021 suggests COVID-19 is associated with long-term cognitive dysfunction and acceleration of Alzheimer's disease pathology and symptoms.
  • Other new data reported at AAIC 2021 included:
    Improving air quality may reduce dementia risk.
  • The Alzheimer's Association International Conference (AAIC) is the world's largest gathering of researchers from around the world focused on Alzheimer's and other dementias.
  • The Alzheimer's Association is a worldwide voluntary health organization dedicated to Alzheimer's care, support and research.

COVID-19 Associated With Long-Term Cognitive Dysfunction, Acceleration Of Alzheimer's Symptoms

Retrieved on: 
Thursday, July 29, 2021
Coronaviridae, Sarbecovirus, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, COVID-19, Severe acute respiratory syndrome coronavirus, Severe acute respiratory syndrome, Long Covid, Impact of COVID-19 on neurological, psychological and other mental health outcomes

New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.

Key Points: 
  • New research reported at the Alzheimer's Association International Conference (AAIC) 2021 , held virtually and in Denver found associations between COVID-19 and persistent cognitive deficits, including the acceleration of Alzheimer's disease pathology and symptoms.
  • Of the patients, 158 were positive for SARS-CoV-2 with neurological symptoms and 152 were positive for SARS-CoV-2 without neurologic symptoms.
  • "These findings suggest that patients who had COVID-19 may have an acceleration of Alzheimer's-related symptoms and pathology," said Wisniewski.
  • Olfactory dysfunction and chronic cognitive impairment following SARS-CoV-2 infection in a sample of older adults from the Andes mountains of Argentina.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Protein O-GlcNAcase, Neurological disorders, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Dementia

Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.

Asceneuron CEO Dirk Beher to Speak at Alzheimer's Association International Conference

Retrieved on: 
Wednesday, July 28, 2021
Branches of biology, Biology, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Protein O-GlcNAcase, O-GlcNAc, Alzheimer's disease, Parkinson's disease, Tau protein

LAUSANNE, Switzerland and SAN FRANSICO, July 28, 2021 /PRNewswire/ -- Asceneuron SA, a clinical-stage biotech company dedicated to targeting the root cause of neurodegenerative diseases, is pleased to announce that Chief Executive Officer, Dirk Beher has been invited to present at The Peter Davies Memorial Symposium: The Future of Tau Based Therapies during the prestigious Alzheimer's Association International Conference which takes place between the 26 – 30 July 2021 in Denver, USA and online. The talk will take place on Wednesday, 28 July at 08:00am MDT / 4:00pm CET.

Key Points: 
  • Dr Dirk Beher will discuss the topic "O-GlcNAcase Inhibitors as Therapies for Tauopathies" and will provide an update on the current status of Asceneuron'sO-GlcNAcase inhibitor research and clinical pipeline.
  • The Alzheimer's Association International Conference is the largest and most influential international meeting dedicated to advancing dementia science.
  • Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson's Disease, Alzheimer's disease and related disorders.
  • The Peter Davies Memorial Symposium: The Future of Tau Based Therapies (preclinical, early phase, current studies, future)

Global Dementia Cases Forecasted To Triple By 2050

Retrieved on: 
Tuesday, July 27, 2021
Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Abnormal psychology, Branches of biology

DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.

Key Points: 
  • DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
  • Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
  • They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
  • The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.

Memory Health Receives Third Patent For Role In The Prevention And/Or Treatment Of Neurodegenerative Disease

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Cognitive disorders, Psychiatry, Neuroscience, Learning disabilities, Psychiatric diagnosis, Dementia, Alzheimer's disease, Neurodegeneration, Mild cognitive impairment, Disabilities affecting intellectual abilities, Neuroscience of aging

The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.

Key Points: 
  • The Intellectual Property Office of Ireland granted Memory Health the patent bearing the specification number 87241, on June 15, 2021.
  • Memory Health is the only supplement patented specifically for the prevention and/or treatment of neurodegenerative disease.
  • The term Neurodegenerative disease describes a range of conditions such as memory loss, mild cognitive impairment, dementia, and Alzheimer's disease, primarily affecting the neurons in the human brain.
  • Memory Health is the gold standard of brain supplementation, the only patented formula for the prevention and/or treatment of neurodegenerative disease, especially dementia, in human subjects.

Global Dementia Cases Forecasted To Triple By 2050

Retrieved on: 
Tuesday, July 27, 2021
Psychiatry, Psychiatric diagnosis, Cognitive disorders, Learning disabilities, Aging-associated diseases, Dementia, Abnormal psychology, Branches of biology

DENVER, July 27, 2021 /PRNewswire/ -- Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050. Meanwhile, anticipated trends in smoking, high body mass index and high blood sugar are predicted to increase prevalence by nearly the same number: 6.8 million cases. Both according to new global prevalence data reported at the Alzheimer's Association International Conference® (AAIC®) 2021 in Denver and virtually.

Key Points: 
  • DENVER, July 27, 2021 /PRNewswire/ --Positive trends in global education access are expected to decrease dementia prevalence worldwide by 6.2 million cases by the year 2050.
  • Nichols and team found dementia would increase from an estimated 57.4 (50.4 to 65.1) million cases globally in 2019 to an estimated 152.8 (130.8 to 175.6) million cases in 2050.
  • They found an increase of 6.8 million dementia cases globally between 2019 and 2050 due specifically to expected changes in these risk factors.
  • The estimation of the global prevalence of dementia from 1990-2019 and forecasted prevalence through 2050: An analysis for the Global Burden of Disease (GBD) study 2019.